Study Shows Drug Decriminalization Does Not Increase Overdose-Related Deaths
A recent study detailed how drug decriminalization did not increase the risk of overdose-related deaths.
Conducted by Oregon and Washington, a recent study showed how drug decriminalization was not an instigator in overdose-related deaths (1). Drug policy reform has become a hot topic throughout the US. States such as Washington and Oregon have either fully or partially decriminalized drug possession. The study looked at an overview on overdose-related deaths, one-year post-implementation. Results showed that previous thoughts that the two may be connected were proven wrong.
In February 2021, Oregon enacted Measure 110. This showed that the state was suffering from a significant drug problem and that the state needed to expand access for drug treatment (2). Washington also experienced a State Supreme Court decision with the State v. Blake which stated that their felony drug possession law was considered unconstitutional (3).
MyCannabis mentioned that the study detailed (1):
- In Oregon, following the enactment of Measure 110 on February 1, 2021, there was no statistically significant increase in overdose-related deaths compared to its synthetic control.
- The average rate difference post-Measure 110 in Oregon was just 0.268 fatal drug overdoses per 100,000 state population, showing minimal change.
- Similarly, in Washington, after the Washington Supreme Court decision in State v. Blake on February 25, 2021, there was no statistically significant rise in overdose-related deaths compared to its synthetic control.
- The average rate difference post-Blake in Washington was merely 0.112 fatal drug overdoses per 100,000 state population, indicating a minimal shift.
Through the study’s findings, it shows the impact drug decriminalization can have on public health, as well as the need for further discussion on drug policy reform. An important note to take on this research is to remember that the data was only reviewing the short-term effects of decriminalization and that further investigation into the medium- and long-term effects needs to be explored. Drug reform advocates (1) are hopeful that research such as the study from Oregon and Washington, will bring about new data and legislation which will benefit those incarcerated, as well as public health.
References
- Kariuki, L. Decriminalization of Drugs Did Not Result in Increased Overdose-Related Deaths: New Study Finds https://www.mycannabis.com/decriminalization-of-drugs-did-not-result-in-increased-overdose-related-deaths-new-study-finds/. (accessed Oct 6, 2023).
- Drug Addiction Treatment and Recovery Act (Measure 110) https://www.oregon.gov/oha/hsd/amh/pages/measure110.aspx. (accessed Oct 6, 2023).
- State v. Blake Refunds https://snohomishcountywa.gov/6065/State-v-Blake-Refunds#:~:text=Blake%3F-,State%20v.,felony%20drug%20possession%20law%20unconstitutional. (accessed Oct 6, 2023).
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
